10 Best High-Growth Stocks to Diversify Away From Big Tech

Page 1 of 3

The S&P 500 has grown notably top-heavy. The 10 largest companies currently make up about 40% of its value, compared to 20% to 25% for the most of the period since 1980, while technology accounts for nearly 40% of the standard index but only roughly 16% of the equal-weight version. That focus paid off while AI spending boosted the biggest names. That said, things have started to become costly.

On November 19, the S&P 500 dropped 2.02% to 7,175.83, the Nasdaq Composite sank 2.25% to 23,879.20, and the Dow closed below 50,000. Anthropic’s IPO failed to revive the AI trade, and the S&P 500 fell further below its 200-day moving average. Readers interested in the stocks hardest impacted by the latest sequence of tech selloffs can see more in our list of oversold AI stocks that continue to draw analyst interest, and those who want to stay in the buildout can read more about these AI infrastructure stocks to buy for the long-term.

Calls to spread risk have getting been louder across the market. Dryden Pence, chief investment officer at Pence Capital, favors an equal-weight S&P 500 as a core holding because ten stocks make up roughly 40% of the S&P 500 and 50% of the Nasdaq. Moreover, according to Credo’s Benjamin Newton, equal weight increases exposure to industrials, financials, and healthcare. Earnings support the case. Russell Investments said analysts expected third-quarter earnings growth of 20.3% for the Magnificent Seven and 27.7% for the rest of the 493 S&P 500 companies.

The case for looking beyond mega-cap technology is that major tech companies have kept expanding. Their valuations already account for a significant amount of the projected AI-driven earnings acceleration, while an array of healthcare, industrial, consumer, finance, and energy companies are expanding at rates that might surprise investors.

With that in mind, let’s take a look at the 10 best high-growth stocks to diversify away from Big Tech. The stocks below are distinct from our previous coverage of high-growth stocks outside Big Tech, which screened for non-tech companies with a 5-year EPS growth of at least 25%. Readers who want more ideas beyond the mega-caps can make use of both lists.

10 Best High-Growth Stocks to Diversify Away From Big Tech

Our Methodology

For this list, we screened for non-tech stocks that boast a 3-year revenue growth rate of at least 30%. We have also mentioned hedge fund ownership numbers for Q3 2026 to provide insight into smart money sentiments around each stock.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10. argenx SE (NASDAQ:ARGX)

Revenue Growth Over the Past 3 Years: 116.47%

Number of Hedge Fund Holders: 42

Argenx SE is a global biotechnology company developing antibody-based therapies for the treatment of severe autoimmune and rare diseases. The company raked in $1.7 billion in global product net sales, up 54% year-over-year and 13% quarter-over-quarter. Moreover, VYVGART net sales reached $1.7 billion for the quarter and $4.5 billion for the first nine months of 2026, compared to $1.1 billion and $2.9 billion in the same periods in 2025.

Argenx also reported total revenue of $1.75 billion in the third quarter, which exceeded consensus forecasts, while operating profit of $486 million fell short of some analyst expectations. However, the company expects approximately $4 billion in combined R&D and selling, general, and administrative spending in 2026, a 45% increase over 2025. The expense supports an expanded pipeline and the possibility of up to five US launches in 2027, though it also raises the bar for execution.

The Phase 3 ALKIVIA trial provided a crucial proof point. VYVGART Hytrulo had a 15.4-point mean advantage over placebo on the Total Improvement Score at Week 52, with a p-value of 0.0011, while the immune-mediated necrotizing myopathy subgroup had a 14.8-point difference and a p-value of 0.0048. However, the dermatomyositis subgroup demonstrated a 14.5-point numerical advantage that didn’t reach statistical significance. Our review of Argenx’s Phase 3 myositis trial asks whether that miss limits commercial opportunities.

9. Permian Resources Corporation (NYSE:PR)

Revenue Growth Over the Past 3 Years: 33.45%

Number of Hedge Fund Holders: 49

Permian Resources is a pure-play Permian Basin operator. The company announced solid third-quarter earnings, with oil and gas sales jumping 48% year-over-year to $1.96 billion. Oil production averaged 208,000 barrels per day, up roughly 10,000 barrels per day from the second quarter, with total output reaching 458,000 barrels of oil equivalent per day. Despite lower oil prices compared to the previous quarter, the company generated a record adjusted free cash flow of $846 million, or $0.98 per share. It also cut controllable cash expenses to a record low of $7.05 per barrel of oil equivalent, while lifting the midpoint of its 2026 oil production projection to about 202,000 barrels per day, around 11% more than last year.

The main risk remains crude oil price volatility, though regional natural gas constraints ought to be addressed as well. Since oil accounts for around 84% of Permian Resources’ revenue, a prolonged drop in crude prices poses the biggest threat to the company’s free cash flow, despite its industry-low cost structure. Our analysis of Permian Resources explores whether record free cash flow can be sustained in the face of commodity price volatility and gas market pressure. Read about it here.

Page 1 of 3